Core Insights - HeartSciences Inc. is focused on transforming ECGs/EKGs through AI technology to enhance early detection of heart disease [1][4] - The company will present at the Emerging Growth Conference 82, providing insights into its mission and market opportunities [2] - HeartSciences is offering a Regulation A investment opportunity for qualified investors, allowing access to investment terms typically unavailable in public markets [2] Company Overview - HeartSciences utilizes innovative AI-based technology to improve the clinical utility of ECGs, aiming to enhance cardiac screening, especially in frontline clinical settings [4] - The company possesses one of the largest libraries of AI-ECG algorithms and plans to offer these algorithms through a cloud-based solution and a low-cost ECG hardware platform [4] - The MyoVista® wavECG™, the company's first product candidate for FDA clearance, provides diagnostic information related to cardiac dysfunction alongside conventional ECG data [4]

Core Insights - Kinetic Seas Incorporated has launched KineticMD, a secure AI platform for healthcare that operates entirely on-site, ensuring patient data privacy and control [1][3][5] - The platform was co-developed with Dr. Sasoon Moulavi and is initially deployed at the Age – Body – Brain – Stamina Institute, focusing on longevity medicine [2][4] - KineticMD is built on open-source foundations and is optimized for regulatory compliance, making it suitable for various sectors where data control is critical [3][4] Company Overview - Kinetic Seas specializes in secure, on-premise AI solutions and is headquartered in Schaumburg, Illinois [6] - The company aims to deliver high-performance AI tools that safeguard data while driving innovation in healthcare, legal, and enterprise IT [6] Financial Projections - The company anticipates generating approximately $5–10 million in annual revenue from its first contract with ABBSI, indicating strong commercial potential for KineticMD [4]

Core Insights - Spectral AI, Inc. announced that its research partners have won the Best Research Project award at the 2025 Education Awards for their work on diabetic foot ulcers using the DeepView System [1][3] Company Overview - Spectral AI is a Dallas-based predictive AI company focused on medical diagnostics, particularly in wound care, with initial applications for burn patients [4] - The DeepView System utilizes multi-spectral imaging and AI algorithms to provide objective assessments of burn wound healing potential [4] Research and Development - The awarded project demonstrates the integration of real-time multispectral imaging with AI analytics to enhance evaluation and treatment strategies for diabetic foot ulcers [3] - The research validates the clinical value of the DeepView System and contributes to expanding its clinical evidence base [3] Market Positioning - The findings from the research are expected to shape the company's commercialization strategy and position it strongly for broader market entry [3]

Nociscan Solution & Market Opportunity - Nociscan leverages MR Spectroscopy and Augmented Intelligence for patients with pain of spinal origin [9] - Nociscan labels each disc as painful or pain free based upon a biochemical signal and correlation with provocative discography, leading to lower cost, better outcomes, and higher value care [14] - The U S low back & neck pain market represents an ultimate market of $135 billion [17] - The U S lumbar spine market (fusion & non-fusion surgery plus presurgical care) represents an expansion market of $40 billion [16] - The U S lumbar fusion & disc replacement market represents an actionable market of $10 billion [17] Foundational Science & Technology - Elevated Lactate is associated with Nociceptor Activation, Excessive Cellular Demand, Cell Death and Reduced PG Synthesis [23] - Spectroscopy analyzes the chemical composition of tissue, transforming raw spectral data into clear biomarkers [26] - Nociscan uses six ratios for each disc, with pain markers in the numerator and structural integrity markers in the denominator, leveraging AI for major advancements [30, 33] Clinical and Economic Evidence - MRS (NOCI+/–) compared to PD (P/NP) with an accuracy of 87%, sensitivity of 100%, and specificity of 80% [47] - The positive predictive value (PPV) in herniated discs, and negative predictive value (NPV) in non-herniated discs, were 100% [47] - MRS with the Nociscan diagnostic algorithm demonstrates cost-effectiveness dominance over PD for identifying CLBP surgical candidates, with annualized US savings estimated between $283 million and $441 million [51, 53] Intellectual Property & Availability - Aclarion has 23 issued U S Patents and 13 Pending Patent Applications [39, 38] - Over 1,100 Commercial Nociscans have been performed [97]

Company Overview - Lifeward, Ltd. is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [3][4] - The company designs, develops, and commercializes solutions that provide functional and health benefits across various care settings, including clinical environments and home care [3] - Lifeward's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit [3] Upcoming Events - Larry Jasinski, CEO of Lifeward, will present at the Sidoti May Virtual Investor Conference on May 21, 2025, at 10:00 AM EDT [1][2] - The company will also conduct virtual one-on-one meetings with investors on May 21-22, 2025, with free registration available for interested parties [2]

世界卫生组织(WHO)驻华代表马丁·泰勒(Martin Taylor)通过视频为本次研讨会致辞。新加坡工程院院 士、香港中文大学(深圳)数据科学学院执行院长李海洲，北京协和医院纪委书记杨敦干，上海交通大学 医学院附属瑞金医院-上海市数字医学创新中心副主任朱立峰，中国医学装备协会理事长侯岩，四川大 学华西医院常务副院长黄进，中国信息通信研究院云计算与大数据研究所副所长闵栋，西门子医疗系统 有限公司大中华区副总裁陈颀潇，罗氏制药中国肿瘤领域总经理钱巍现场出席并作主题演讲。全国政协 常委、浙江省政协副主席、浙江大学医学院附属邵逸夫医院院长蔡秀军以视频方式发表演讲。 中国经济网北京5月18日讯(记者 李方) 5月17日下午，由世界互联网大会人工智能专委会主办的"数字转 型创新、智绘健康未来"研讨会在北京国家会议中心召开。中国国家互联网信息办公室副主任王京涛、 世界互联网大会秘书长任贤良出席会议并致辞，世界互联网大会常务副秘书长梁昊主持会议。 会议认为，当前数字技术正以前所未有的深度和广度重塑医疗健康生态系统，数字化转型和人工智能技 术是推动医疗健康迈向高质量发展的关键引擎。会议就促进人工智能赋能医疗健康提出三点建议： ...

Core Insights - Omnicell has launched new products, including RFID products under the MedTrack line and a web-enabled software named MedVision, aimed at improving medication management and workflow efficiency in healthcare settings [1][4][6] - The company’s market capitalization is currently $1.31 billion, with a projected revenue growth of 1.4% for 2025 according to Zacks Consensus Estimate [3] - The global Hospital Asset Tracking and Inventory Management Systems market is expected to reach $31.05 billion by 2025, growing at a CAGR of 5.5% through 2030, indicating a favorable industry environment for Omnicell [10] Company Developments - The MedTrack line includes MedTrack – OR, which is designed to enhance medication tracking in operating rooms and streamline workflows during surgical emergencies [5] - MedVision software facilitates real-time inventory management for outpatient clinics, allowing automatic reordering from central pharmacies when stock levels are low [6][7] - Omnicell has opened an Innovation Lab in Austin, Texas, to develop new technologies addressing challenges in medication and supply management [11] Market Sentiment - Following the product announcements, Omnicell shares remained stable in after-hours trading, with expectations that the new solutions will enhance market sentiment towards the stock [2] - Over the past three months, Omnicell shares have declined by 27.4%, contrasting with a 9.5% decline in the broader industry [12]

Financial Data and Key Metrics Changes - The company reported a net income of $18.6 million for the first quarter, resulting in a positive primary EPS of $1.28 and a positive diluted EPS of $0.34 [23][24]. - A significant liability reduction of approximately $25 million was achieved, primarily from a reduction in convertible notes and accrued expenses [19][20]. - The company ended the quarter with $40 million in pro forma cash, extending its runway well into 2026 [11]. Business Line Data and Key Metrics Changes - Lucid, the company's diagnostic subsidiary, reported revenue of $800,000 with a test volume of 3,034, meeting the target range [10]. - Verus has restarted the development of a key implantable physiologic monitor after securing financing [12][14]. - The incubator PMX is focused on advancing technologies, particularly the PortIO device, with ongoing discussions with strategic partners [8][14]. Market Data and Key Metrics Changes - The company is seeing momentum in new sales channels, particularly in concierge medicine and employer market contracts, which are expected to impact revenue in the second half of the year [11][12]. - The company is awaiting a response from the MolDX program regarding Medicare coverage for EsoGuard, which is anticipated to be imminent [12]. Company Strategy and Development Direction - The company aims to diversify into the biopharma space, leveraging its infrastructure and management services model to capitalize on early-stage assets in oncology and cardiometabolic areas [9][39]. - The strategic focus includes expanding partnerships and exploring new assets that fit within the shared services model [10][39]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning and ability to execute its strategic vision, highlighting the potential value creation from Lucid and Verus [51][52]. - The company is optimistic about leveraging its model and infrastructure to pursue significant opportunities in the near future [52][53]. Other Important Information - The company has deconsolidated Lucid from its financial statements, which will affect year-over-year comparisons in the upcoming quarters [16][22]. - PAVmed remains the largest shareholder of Lucid, holding approximately 29% of the common shares outstanding [20]. Q&A Session Summary Question: Feedback from the pilot program - Management received excellent feedback from the pilot program, with all pre-specified performance metrics met and enthusiasm from academic medical centers [31][32]. Question: Exclusive rights to the platform - There are local rights for advancing the platform, but no exclusivity that limits broader commercialization efforts [34][35]. Question: Rationale for expanding into biopharma - The company is leveraging its adjusted corporate structure and management services to explore opportunities in biopharma, particularly in early-stage assets that require clinical research [39][40]. Question: Impact of market volatility on capital raising - Management indicated that market volatility has not significantly affected their ability to raise capital, with successful financing in the first quarter [47][48].

Financial Data and Key Metrics Changes - Trisalis Life Sciences reported net sales of $9.2 million for Q1 2025, representing a 42% increase compared to Q1 2024 and an 11% sequential gain over Q4 2024 [9][23] - The company achieved a gross margin of 84% in Q1 2025, slightly down from 85% in Q1 2024, attributed to decreased factory volumes during a clean room expansion [24] - Operating losses for Q1 2025 totaled $7.3 million, a decrease from $11.7 million in Q1 2024, primarily due to increased sales and reduced R&D expenses [25] - Adjusted EBITDA losses for Q1 2025 were $5.5 million, compared to losses of $10.4 million in Q1 2024 [27] Business Line Data and Key Metrics Changes - The company maintained strong momentum in the liver embolization market, increasing the number of unique ordering accounts by 39% year-over-year, adding 32 new accounts in Q1 2025 [11][12] - The launch of TriNav Large and TriGuide expanded the PEDD technology into larger vessels, supporting deeper penetration in the liver market [15] Market Data and Key Metrics Changes - Trisalis has achieved a market share of 10% in liver taste and tear procedures, reflecting growth driven by the adoption of TriNav in new accounts and increased utilization [23] - The Centers for Medicare and Medicaid Services issued a new HCPCS code C8004, providing coverage for mapping procedures using TriNet, effectively doubling the reimbursable use of the technology [12] Company Strategy and Development Direction - The company is focusing on deepening penetration in the liver embolization market, advancing TriNav Flex and TriNav Large, and generating new health economic and outcome research data [19][20] - A shift to a partnership-focused strategy for nalotolimod is expected to eliminate development expenses while preserving long-term value [9][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving at least 50% revenue growth for 2025, despite not anticipating being EBITDA positive or cash flow positive in the year [20] - The company is optimistic about the momentum built from recent strategic initiatives and the potential for new clinical applications [19][21] Other Important Information - Trisalis raised approximately $22 million in gross proceeds through a private placement, strengthening its balance sheet for future investments [18][27] - The company is implementing an exchange offer to convert preferred shares to common stock, simplifying its capital structure [18] Q&A Session Summary Question: What should be looked for in the PERIO three readout? - Management highlighted the focus on the device's functionality and safety profile, as well as the potential to stimulate the innate environment of pancreatic tumors [36] Question: Is there interest in nalotolimod independently or in conjunction with TriNav? - Management clarified that nalotolimod's optimal delivery is through their technology, and they expect to partner with pharmaceutical companies for combined trials [40] Question: Feedback on TriNav Large and its adoption? - Initial adoption is strong among larger tumors and uterine fibroid embolization, with positive results reported by physicians [46] Question: Impact of clean room expansion on gross margins? - The clean room expansion was completed in March, and gross margins are expected to improve in the upcoming quarters [50] Question: How will the sales force expansion impact growth rates? - The company plans to add sales resources to accelerate growth, with the most significant impact expected in 2026 [55] Question: Feedback on the new mapping code? - Early feedback is favorable, with physicians using the device more consistently due to full reimbursement [58] Question: Commercial organization expansion and account numbers? - The company currently has around 300 accounts and aims to expand its sales force to 60-70 representatives over the next 18 months [79]

Financial Data and Key Metrics Changes - Trisalis Life Sciences reported net sales of $9.2 million for Q1 2025, representing a 42% increase compared to Q1 2024 and an 11% sequential gain over Q4 2024 [8][22] - The company achieved a gross margin of 84% in Q1 2025, slightly down from 85% in Q1 2024, attributed to decreased factory volumes during a clean room expansion [23] - Operating losses for Q1 2025 totaled $7.3 million, a decrease from $11.7 million in Q1 2024, primarily due to increased sales and reduced R&D expenses [24] - Adjusted EBITDA losses for Q1 2025 were $5.5 million, down from $10.4 million in Q1 2024, reflecting improved sales and reduced expenses [25] Business Line Data and Key Metrics Changes - The company maintained strong momentum in the liver embolization market, increasing the number of unique ordering accounts by 39% compared to Q1 2024, adding 32 new accounts [10] - The TriNav device's market share in liver procedures reached 10%, with a compound annual growth rate of approximately 50% since its launch in 2020 [22] Market Data and Key Metrics Changes - The Centers for Medicare and Medicaid Services issued a new HCPCS code C8004, providing coverage for mapping procedures using TriNav, effectively doubling the reimbursable use of the technology [11] - The company is expanding its technology into new clinical settings, including a multicenter registry evaluating PEDD for patients with thyroid nodules [13] Company Strategy and Development Direction - The company is focusing on deepening penetration in the liver embolization market, advancing TriNav technology, and preparing nalotolimod for pharmaceutical partnerships [7][18] - Strategic priorities include driving adoption of PEDD across solid tumors, improving manufacturing and gross margins, and expanding the product portfolio [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving at least 50% revenue growth for 2025, despite not anticipating being EBITDA positive or cash flow positive in the year [19] - The company is entering the rest of 2025 with strong tailwinds and plans to invest in strategic areas to drive long-term value [19][20] Other Important Information - The company raised approximately $22 million in gross proceeds through a private placement, strengthening its balance sheet for further investments [16] - The completion of Phase I trials for nalotolimod allows the company to shift to a partnership-focused strategy, reducing development expenses [15] Q&A Session Summary Question: What should be looked for in the PERIO three readout? - Management highlighted the focus on the device's functionality and safety profile, as well as the potential to stimulate the innate environment of pancreatic tumors [30][34] Question: Is there interest in nalotolimod independently or in conjunction with TriNav? - Management indicated that nalotolimod's performance is optimized through their technology, and they expect to partner with pharmaceutical companies for combined development [35][38] Question: Feedback on TriNav Large and its adoption? - Initial adoption is strong among physicians treating larger tumors, with positive results reported [41][43] Question: Impact of clean room expansion on gross margins? - The clean room expansion was completed in March, and gross margins are expected to improve in the upcoming quarters [45][46] Question: How will the sales force expansion impact growth rates? - The company plans to add sales resources to accelerate growth, with the most significant impact expected in 2026 [50][51] Question: Feedback on the new mapping code? - Early feedback is favorable, with physicians using the device more consistently due to full reimbursement [52][54] Question: What is the current number of accounts and future goals? - The company has around 300 accounts and aims to increase its sales force to cover more hospitals [73][76]